Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogene
Autors principals: Bencomo-Alvarez, Alfonso E., Rubio, Andres J., Olivas, Idaly M., Gonzalez, Mayra A., Ellwood, Rebecca, Fiol, Carme Ripoll, Eide, Christopher A., Lara, Joshua J., Barreto-Vargas, Christian, Jave-Suarez, Luis F., Nteliopoulos, Georgios, Reid, Alistair G., Milojkovic, Dragana, Druker, Brian J., Apperley, Jane, Khorashad, Jamshid S., Eiring, Anna M.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952820/
https://ncbi.nlm.nih.gov/pubmed/33712704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-021-01732-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars